BioCer Entwicklungs GmbH

Bayreuth, Germany

BioCer Entwicklungs GmbH

Bayreuth, Germany

Time filter

Source Type

Douard N.,University of Limoges | Detsch R.,BioCer Entwicklungs GmbH | Chotard-Ghodsnia R.,University of Limoges | Damia C.,University of Limoges | And 2 more authors.
Materials Science and Engineering C | Year: 2011

For bone grafting applications, the elaboration of silicon containing beta-tricalcium phosphate (β-TCP) was studied. The synthesis was performed using a wet precipitation method according to the hypothetical theoretical formula Ca3 - x(PO4)2 - 2x(SiO 4)x. Two silicon loaded materials (0.46 wt.% and 0.95 wt.%) were investigated and compared to a pure β-TCP. The maturation time of the synthesis required in order to obtain β-TCP decreased with the amount of silicon. Only restrictive synthesis conditions allow preparing silicon containing β-TCP with controlled composition. To obtain dense ceramics, the sintering behaviour of the powders was evaluated. The addition of silicon slowed the densification process and decreased the grain size of the dense ceramics. Rietveld refinement may indicate a partial incorporation of silicon in the β-TCP lattice. X-ray photoelectron spectroscopy and transmission electron microscopy analyses revealed that the remaining silicon formed amorphous clusters of silicon rich phase. The in vitro biological behaviour was investigated with MC3T3-E1 osteoblast-like cells. After the addition of silicon, the ceramics remained cytocompatible, highlighting the high potential of silicon containing β-TCP as optimised bone graft material. © 2010 Elsevier B.V. All rights reserved.


News Article | November 16, 2016
Site: www.newsmaker.com.au

Notes: Production, means the output of Hemostats Revenue, means the sales value of Hemostats This report studies Hemostats in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Ethicon, Inc. Pfizer, Inc. Baxter International Inc. C. R. Bard The Medicines Company Anika Therapeutics, Inc Advanced Medical Solutions Integra LifeSciences Corporation B Braun Melsungen AG Gelita Medical GmbH Equimedical Vascular Solutions, Inc Marine Polymer Technologies, Inc. Z-Medica, LLC CryoLife, Inc. BioCer Entwicklungs-GmbH Biom’Up SAS By types, the market can be split into Thrombin-Based Hemostats Oxidized Regenerated Cellulose Based Hemostats Combination Hemostats Gelatin Based Hemostats Collagen Based Hemostats By Application, the market can be split into Prehospital Treatment Hospital Treatment Application 3 By Regions, this report covers (we can add the regions/countries as you want) United States EU Japan China India Southeast Asia Notes: Production, means the output of Hemostats Revenue, means the sales value of Hemostats This report studies Hemostats in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, with production, revenue, consumption, import and export in these regions, from 2011 to 2015, and forecast to 2021. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering Ethicon, Inc. Pfizer, Inc. Baxter International Inc. C. R. Bard The Medicines Company Anika Therapeutics, Inc Advanced Medical Solutions Integra LifeSciences Corporation B Braun Melsungen AG Gelita Medical GmbH Equimedical Vascular Solutions, Inc Marine Polymer Technologies, Inc. Z-Medica, LLC CryoLife, Inc. BioCer Entwicklungs-GmbH Biom’Up SAS By types, the market can be split into Thrombin-Based Hemostats Oxidized Regenerated Cellulose Based Hemostats Combination Hemostats Gelatin Based Hemostats Collagen Based Hemostats By Application, the market can be split into Prehospital Treatment Hospital Treatment Application 3 By Regions, this report covers (we can add the regions/countries as you want) United States EU Japan China India Southeast Asia List of Tables and Figures Figure Picture of Hemostats Table Product Specifications of Hemostats Table Classification of Hemostats Figure Global Production Market Share of Hemostats by Type in 2015 Figure Thrombin-Based Hemostats Picture Table Major Manufacturers of Thrombin-Based Hemostats Figure Oxidized Regenerated Cellulose Based Hemostats Picture Table Major Manufacturers of Oxidized Regenerated Cellulose Based Hemostats Figure Combination Hemostats Picture Table Major Manufacturers of Combination Hemostats Figure Gelatin Based Hemostats Picture Table Major Manufacturers of Gelatin Based Hemostats Figure Collagen Based Hemostats Picture Table Major Manufacturers of Collagen Based Hemostats Table Applications of Hemostats Figure Global Consumption Volume Market Share of Hemostats by Application in 2015 Figure Prehospital Treatment Examples Table Major Consumers of Prehospital Treatment Figure Hospital Treatment Examples Table Major Consumers of Hospital Treatment Figure Market Share of Hemostats by Regions Figure United States Hemostats Market Size (2011-2021) Figure EU Hemostats Market Size (2011-2021) Figure Japan Hemostats Market Size (2011-2021) Figure China Hemostats Market Size (2011-2021) Figure India Hemostats Market Size (2011-2021) Figure Southeast Asia Hemostats Market Size (2011-2021) Table Hemostats Raw Material and Suppliers FOR ANY QUERY, REACH US @    Hemostats Global Market Professional Survey Research Report 2016


News Article | November 22, 2016
Site: www.newsmaker.com.au

Hemostats are agents used to compress or treat bleeding vessels in order to arrest hemorrhage. These products may reduce operating room time and decrease the number of blood transfusions required in surgical procedures. Hemostatic agents are available in various forms including pads, sponges, liquids, and powders. The ideal agent should be: Able to stop hemorrhage from large arteries and veins within two minutes of application Capable of effective application through pools of blood, packaged as a ready to use agent Simple to use even by non-medically trained responders Lightweight and durable Capable of extended storage under a wide range of temperatures Inexpensive Free from bacterial or viral risk This report focuses on the Hemostats in Global market, especially in North America, Europe and Asia-Pacific, Latin America, Middle and Africa. This report categorizes the market based on manufacturers, regions, type and application. Ethicon, Inc., Pfizer, Inc., Baxter International Inc., C. R. Bard, The Medicines Company, Anika Therapeutics, Inc., Advanced Medical Solutions, Integra LifeSciences Corporation, B Braun Melsungen AG, Gelita Medical GmbH, Equimedical, Vascular Solutions, Inc., Marine Polymer Technologies, Inc., Z-Medica, LLC, CryoLife, Inc., BioCer Entwicklungs-GmbH. To Know More, Ask Our Expert @ http://www.intenseresearch.com/market-analysis/global-hemostats-market-by-manufacturers-regions-type-and.html#inquiry-for-buying


Detsch R.,BioCer Entwicklungs GmbH | Hagmeyer D.,University of Duisburg - Essen | Neumann M.,University of Duisburg - Essen | Schaefer S.,University of Bayreuth | And 5 more authors.
Acta Biomaterialia | Year: 2010

Nanocrystalline calcium phosphates containing carbonate have a high similarity to bone mineral. The reactions of bone cells (primary osteoblasts and osteoclast-like cells) on these materials as well as on sintered β-tricalcium phosphate and hydroxyapatite (HA) confirmed a good biocompatibility of the nanocrystalline samples. However, osteoclastic differentiation was constrained on the carbonate-rich samples, leading to a small number of osteoclast-like cells on the materials and few resorption pits. The grain size of the calcium phosphate ceramics (nano vs. micro) was less important than expected from to physico-chemical considerations. When comparing the nanocrystalline samples, the highest resorption rate was found for nano-HA with a low carbonate content, which strongly stimulated the differentiation of osteoclast-like cells on its surface. © 2010 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.


Haenle M.,University of Rostock | Fritsche A.,University of Rostock | Zietz C.,University of Rostock | Bader R.,University of Rostock | And 3 more authors.
Journal of Materials Science: Materials in Medicine | Year: 2011

Implant infections remain feared and severe complications after total joint arthroplasty. The incidence of multi-resistant pathogens, causing such infections, is rising continuously, and orthopaedic surgeons are confronted with an ever-changing resistance pattern. Anti-infectious surface coatings aim for a high local effective concentration and a low systemic toxicity at the same time. Antibacterial efficacy and biomechanical stability of a novel broad-spectrum anti-infectious coating is assessed in the present study. Antibacterial efficacy of a sol-gel derived titanium dioxide (TiO2) coating for metal implants with and without integrated copper ions as antibiotic agent was assessed against methicillin resistant Staphylococcus aureus (MRSA 27065). Both bacterial surface adhesion and growth of planktonic bacteria were assessed with bare and various TiO2-coated Ti6Al4V metal discs. Furthermore, bonding strength of the TiO2 surface coating, using standard testing procedures, as well as surface roughness were determined. We found a significant reduction of the bacterial growth rate for the coatings with integrated copper ions, with highest reduction rates observed for a fourfold copper TiO2-coating. Pure TiO2 without integrated copper ions did not reduce bacterial growth compared to uncoated Ti6Al4V. The coating was not detached from the substrate by standard adhesive failure testing, which indicated an excellent durability of the implant coating. The TiO2 coating with integrated copper ions could offer a new strategy for preventing implant-associated infections, with antibacterial properties not only against the most common bacteria causing implant infections but also against multiresistant strains such as MRSA. © 2010 Springer Science+Business Media, LLC.


Schumacher M.,University of Bayreuth | Uhl F.,BioCer Entwicklungs GmbH | Detsch R.,BioCer Entwicklungs GmbH | Deisinger U.,University of Bayreuth | And 2 more authors.
Journal of Materials Science: Materials in Medicine | Year: 2010

The adequate regeneration of large bone defects is still a major problem in orthopaedic surgery. Synthetic bone substitute materials have to be biocompatible, biodegradable, osteoconductive and processable into macroporous scaffolds tailored to the patient specific defect. Hydroxyapatite (HA) and tricalcium phosphate (TCP) as well as mixtures of both phases, biphasic calcium phosphate ceramics (BCP), meet all these requirements and are considered to be optimal synthetic bone substitute materials. Rapid prototyping (RP) can be applied to manufacture scaffolds, meeting the criteria required to ensure bone ingrowth such as high porosity and defined pore characteristics. Such scaffolds can be used for bone tissue engineering (BTE), a concept based on the cultivation of osteogenic cells on osteoconductive scaffolds. In this study, scaffolds with interconnecting macroporosity were manufactured from HA, TCP and BCP (60 wt% HA) using an indirect rapid prototyping technique involving wax ink-jet printing. ST-2 bone marrow stromal cells (BMSCs) were seeded onto the scaffolds and cultivated for 17 days under either static or dynamic culture conditions and osteogenic stimulation. While cell number within the scaffold pore system decreased in case of static conditions, dynamic cultivation allowed homogeneous cell growth even within deep pores of large (1,440 mm3) scaffolds. Osteogenic cell differentiation was most advanced on BCP scaffolds in both culture systems, while cells cultured under perfusion conditions were generally more differentiated after 17 days. Therefore, scaffolds manufactured from BCP ceramic and seeded with BMSCs using a dynamic culture system are the method of choice for bone tissue engineering. © 2010 Springer Science+Business Media, LLC.


Schumacher M.,University of Bayreuth | Deisinger U.,University of Bayreuth | Ziegler G.,University of Bayreuth | Ziegler G.,BioCer Entwicklungs GmbH | Detsch R.,BioCer Entwicklungs GmbH
Journal of Materials Science: Materials in Medicine | Year: 2010

While various materials have been developed for bone substitute and bone tissue engineering applications over the last decades, processing techniques meeting the high demands of scaffold shaping are still under development. Individually adapted and mechanically optimised scaffolds can be derived from calcium phosphate (CaP-) ceramics via rapid prototyping (RP). In this study, porous ceramic scaffolds with a periodic pattern of interconnecting pores were prepared from hydroxyapatite, β- tricalcium phosphate and biphasic calcium phosphates using a negative-mould RP technique. Moulds predetermining various pore patterns (round and square cross section, perpendicular and 60° inclined orientation) were manufactured via a wax printer and subsequently impregnated with CaP-ceramic slurries. Different pore patterns resulted in macroporosity values ranging from about 26.0-71.9 vol% with pore diameters of approximately 340 μm. Compressive strength of the specimens (1.3-27.6 MPa) was found to be mainly influenced by the phase composition as well as the macroporosity, both exceeding the influence of the pore geometry. A maximum was found for scaffolds with 60 wt% hydroxyapatite and 26.0 vol% open porosity. It has been shown that wax ink-jet printing allows to process CaP-ceramic into scaffolds with highly defined geometry, exhibiting strength values that can be adjusted by phase composition and pore geometry. This strength level is within and above the range of human cancellous bone. Therefore, this technique is well suited to manufacture scaffolds for bone tissue engineering. © Springer Science+Business Media, LLC 2010.


Schaefer S.,University of Bayreuth | Detsch R.,BioCer Entwicklungs GmbH | Uhl F.,BioCer Entwicklungs GmbH | Deisinger U.,University of Bayreuth | Ziegler G.,BioCer Entwicklungs GmbH
Advanced Engineering Materials | Year: 2011

The chemical composition of calcium phosphate (CaP) materials for the regenerative therapy of large bone defects is similar to that of bone. Additionally, calcium phosphates show an excellent biocompatibility. Besides the support of defect healing calcium phosphate implants should be completely degraded within an adequate time period to be replaced by newly formed bone. Although degradation of CaP-implants occurs mainly by dissolution of the material, it is important to characterize the osteoclastic resorption as well, which is involved in native bone remodeling. The degradation of bone substitutes made of calcium phosphate ceramics is influenced by various parameters, such as defect size and localization, the general health situation, and age of the patient, but also material properties are important. Especially, the calcium phosphate composition is crucial for the degradation behavior of a calcium phosphate material. Additionally, at the cellular level the micro- and macroporosity, including interconnecting pores, influences both, the dissolution and the osteoclastic resorption. In our study, three different calcium phosphate materials (hydroxyapatite, tricalcium phosphate, and a biphasic calcium phosphate) and two different geometries (dense 2D samples and porous 3D scaffolds) are compared regarding their dissolution and resorption behavior. The results show, that the dissolution of CaP-ceramics, as examined by the incubation in a degradation solution, depends mainly on the calcium phosphate phase but also on the porosity of the implant. Regarding the resorption, cell proliferation and differentiation of a monocytic cell line as well as the formation of resorption lacunas are analyzed. Cell proliferation is comparable on all phase compositions. Cell differentiation and resorption, however, are influenced by the calcium phosphate phase composition and by the implant porosity as well. By understanding these two mechanisms of degradation, bone substitute materials and, as a result, the bone regeneration of large bone defects using CaP-ceramics can be improved. Degradation of synthetic calcium phosphates that are used for bone substitution is defined by both chemical dissolution (physicochemical degradation) and resorption (cellular degradation by osteoclasts). In summary, the degradation mechanisms depend on both, the calcium phosphate composition and the sample micro- and macroporosity. Therefore, degradation of a bone substitute can be adjusted in the individual case by both parameters, whereby phase composition has a greater influence than sample porosity. Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA.


Trademark
BioCer Entwicklungs GmbH | Date: 2015-07-14

Styptic preparations, namely, haemostatic substances in powder form to stop bleeding during surgery. Products for medical purposes, namely, dispensers and applicators for dispensing and applying haemostatic substances in powder form to stop bleeding during surgery.


Trademark
BioCer Entwicklungs GmbH | Date: 2015-07-21

surgical implants of artificial materials.

Loading BioCer Entwicklungs GmbH collaborators
Loading BioCer Entwicklungs GmbH collaborators